# A041703 (NCT03739814)

> Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

No report yet. It can be ordered.

- Drugs tested: inotuzumab ozogamicin plus blinatumomab; inotuzumab ozogamicin plus blinatumomab plus ponatinib
- Indication: CD22-positive B-cell acute lymphoblastic leukemia

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03739814
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Recurrent B Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia
- Interventions: Biospecimen Collection; Blinatumomab; Bone Marrow Aspiration; Bone Marrow Biopsy; Inotuzumab Ozogamicin; Lumbar Puncture; Ponatinib
- Enrollment: 84
- Primary outcome: Event-free survival
- Primary outcome: Completion of protocol treatment (cohort 3)

## Indexed commentary on A041703 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 9
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=a041703-nct03739814

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03739814", "email": "<work email>"}; the inbox owner confirms by the emailed link.